Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment
| Autor: | M. Kuhn, T. A. Scherer, F. Blauer, M. C. Fleisch, J. G. H. Gubler |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Biopsy government.form_of_government Internal medicine medicine Eosinophilic pneumonia Humans Eosinophilia Pulmonary Eosinophilia Lung Depressive Disorder Major business.industry Respiratory disease Venlafaxine Hydrochloride respiratory system Cyclohexanols medicine.disease respiratory tract diseases Pneumonia medicine.anatomical_structure Respiratory failure Acute eosinophilic pneumonia Acute Disease Immunology government Antidepressive Agents Second-Generation Prednisone medicine.symptom Respiratory Insufficiency Tomography X-Ray Computed business |
| Zdroj: | European Respiratory Journal. 15:205-208 |
| ISSN: | 0903-1936 |
| DOI: | 10.1183/09031936.00.15120500 |
| Popis: | Drugs are well known causes of eosinophilic lung disease. In many patients, symptoms increase slowly, pulmonary infiltrates and eosinophilia progress over weeks, and resolve upon withdrawal of the offending agent. Rarely, the disease presents like acute eosinophilic pneumonia with acute onset of symptoms and rapidly progressing infiltrates which may be associated with respiratory failure. This report describe a case of venlafaxine-induced acute eosinophilic pneumonia causing respiratory insufficiency that rapidly resolved upon institution of corticosteroid treatment. This 5-hydroxytryptamine and noradrenaline reuptake inhibitor was previously not known to cause lung or peripheral blood eosinophilia. Considering the increasing use of this class of medication physicians have to be aware of this life-threatening and fully reversible complication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text